GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL

Generium

Status and phase: Enrolling; Phase 2; Phase 1

Conditions: GNR-084; ALL; B-precursor Acute Lymphoblastic Leukemia

Treatments: Biological: Cohort 3, GNR-084; Biological: Cohort 5, GNR-084; Biological: Cohort 2, GNR-084; Biological: Cohort 1, GNR-084; Biological: Cohort 6, GNR-084; Biological: Cohort 4, GNR-084

Study type: Interventional

Funder types: Industry

Identifiers

NCT04601584

#652 eff date 12.11.2019 (Other Identifier)

BIM-HEM-I

Details and patient eligibility

About

It is an open-label dose-escalating study in sequential cohorts to assess safety and pharmacokinetics of GNR-084.

Full description

Acute lymphoblastic leukemias (ALL) are a heterogeneous group of malignant clonal diseases of the blood system originating from precursor cells of hematopoiesis, predominantly of lymphoid differentiation.

More than 7,200 new cases of ALL are diagnosed annually in the European Union (EU), with approximately 40% (approximately 3,000 cases) occurring in adults The main reason for the failure of treatment of acute B-cell lymphoblastic leukemias (B-ALL) is the primary refractoriness to chemical exposure and relapses of the disease, which actually occur in 40-50% of adult patients with ALL. The prognosis in these cases is regarded as extremely unfavorable. Escalation of the chemotherapeutic approach is associated with the development of severe toxic infectious and hemorrhagic complications.

The active substance of the preparation GNR-084 is a bispecific antibody to CD19 / CD3 in the BiMS format (bispecific IgG-like molecules).

Enrollment: 36 estimated patients

Sex: All

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Voluntarily signed informed consent form to participate in the study;
2. Men and women between aged 18 to 45 inclusive;
3. Patients with incurable morphologically / immunophenotypically confirmed refractory/ relapse of B-cell precursors CD19-positive acute lymphoblastic leukemia from (Ph "-" or Ph "+").
4. Two or more previous lines of anti-leucosis therapy.
5. 5-50% of bone marrow blast cells at screening;
6. Functional status on the scale of the Eastern Cooperative Oncology Group (ECOG) 0-2 points at the screening;
7. Life expectancy ≥ 60 days;

Exclusion criteria

1. Hematopoietic stem cells transplantation within 12 weeks prior to study inclusion;

2. Active and widespread chronic graft versus host (GVHD) reaction (grade II-IV), including taking immunosuppressants for the prevention and treatment of GVHD within 2 weeks prior the GNR-084 infusion;

3. Investigator and / or sponsor has doubts that patient will complete the study due to rapid disease progression;

4. Chemotherapeutic agent using within 14 days prior the first GNR-084 infusion;

   Exceptions:

   • Emergency leukapheresis;
   • Emergency hydroxyurea using due to hyperleukocytosis for ≤ 7 days;
   • Other supportive care, including antibiotics, at Investigator's discretion

5. Biochemical blood test:

   • The level of total bilirubin> 1.5 upper limit of norm;
   • Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT)> 3 upper limit of norm;
   • Glomerular filtration rate (GFR) level ≤30 (СKD-EPI)

6. Medical history of blinatumomab and other bispecific antibodies using;

7. Persistent toxicity event of 3rd and 4th severity degrees (CTCAE ver 5.0) due to previous treatment;

8. HIV-positive status and / or detection of any hepatitis B and / or hepatitis C blood markers;

9. Severe cardiovascular diseases: uncontrolled arterial hypertension, New York Heart Association (NYHA) functional class III or IV chronic heart failure, unstable angina pectoris, stroke, myocardial infarction, transient ischemic attack, coronary artery bypass grafting and coronary revascularization within last 12 months, or signs of pericardial effusion;

10. Individual sensitivity to:

    • GNR-084 components / excipients;
    • human or humanized investigational drug antibodies;

11. Major surgical interventions, accompanied by hospitalization and anesthesia application within 30 days before the patient is included in the study (biopsy is not a significant surgical intervention);

12. Any other malignant neoplasm presence at the present time or within 5 years prior to inclusion in the study;

13. Known suspected Central Nervous System (CNS) lesion by any genesis now or in medical history, including, but not limited to: neuroleukemia, epilepsy, ischemic or hemorrhagic stroke, severe traumatic brain injury, dementia, Parkinson's disease, organic brain damage, cerebellar disorders, psychosis;

14. Extramedullary lesion of any localization;

15. Other clinical trials participation within 30 days before screening;

16. Mental, physical and other reasons hindering patient to adequately assess their behavior and correctly comply with the conditions of the research protocol;

17. Pregnancy and / or lactation;

18. Male and female patients refusal to use adequate methods of contraception throughout the study;

19. Drug addiction;

20. Alcohol addiction.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

36 participants in 6 patient groups

GNR-084, dose level 1

Experimental group

Description:

Anti-CD19/CD3 antibody

Treatment:

Biological: Cohort 1, GNR-084

GNR-084, dose level 2

Experimental group

Description:

Anti-CD19/CD3 antibody

Treatment:

Biological: Cohort 2, GNR-084

GNR-084, dose level 3

Experimental group

Description:

Anti-CD19/CD3 antibody

Treatment:

Biological: Cohort 3, GNR-084

GNR-084, dose level 4

Experimental group

Description:

Anti-CD19/CD3 antibody

Treatment:

Biological: Cohort 4, GNR-084

GNR-084, dose level 5

Experimental group

Description:

Anti-CD19/CD3 antibody

Treatment:

Biological: Cohort 5, GNR-084

GNR-084, dose level 6

Experimental group

Description:

Anti-CD19/CD3 antibody

Treatment:

Biological: Cohort 6, GNR-084